{"transactions":[{"id":791919,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:42:20.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1756069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":1756069,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1756069},"source":{"system":"sec-edgar","filing":"0001213900-26-052262","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390026052262/ownership.xml","form_type":"4"}},{"id":985224,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-01T13:56:56.000Z","date":"2025-11-28","kind":"purchase","planned":false,"acquired":true,"shares":33333,"price":0.75,"value":24999.75,"ownership":{"direct":true},"balance_after":73334,"source":{"system":"sec-edgar","filing":"0001213900-25-116301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025116301/ownership.xml","form_type":"4"}},{"id":1013283,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:26:30.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":493341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":493341,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":493341},"source":{"system":"sec-edgar","filing":"0001213900-25-102677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025102677/ownership.xml","form_type":"4"}},{"id":1149367,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-15T01:55:17.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":960,"price":0.825,"value":792.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person previously held 960 shares of Common Stock of the Issuer in a foreign brokerage account that was recently wound down. As a result, the foreign broker automatically liquidated the Reportion Person's account on May 12, 2025 by selling the 960 shares of Common Stock of the Issuer on a non-discretionary basis."}],"balance_after":40001,"source":{"system":"sec-edgar","filing":"0001213900-25-043621","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025043621/ownership.xml","form_type":"4"}},{"id":1546901,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:31.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":11669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":11669,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":11669},"source":{"system":"sec-edgar","filing":"0001213900-24-030963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024030963/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546900,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:31.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-030963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024030963/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1607547,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:21.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":11669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":11669,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":11669},"source":{"system":"sec-edgar","filing":"0001213900-24-019219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024019219/ownership.xml","form_type":"4"}},{"id":1607546,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:21.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-019219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024019219/ownership.xml","form_type":"4"}},{"id":2103502,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-25","kind":"grant","acquired":true,"shares":2000,"price":1.03,"value":2060.0,"ownership":{"direct":true},"balance_after":819206,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103501,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":1206,"price":1.02,"value":1230.12,"ownership":{"direct":true},"balance_after":817206,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103500,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":1000,"price":1.03,"value":1030.0,"ownership":{"direct":true},"balance_after":816000,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103499,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":815000,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2133655,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-21T21:05:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":4400,"price":1.07,"value":4708.0,"ownership":{"direct":true},"balance_after":810000,"source":{"system":"sec-edgar","filing":"0001213900-22-065571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022065571/ownership.xml","form_type":"4"}},{"id":2133654,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-21T21:05:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":600,"price":1.08,"value":648.0,"ownership":{"direct":true},"balance_after":805600,"source":{"system":"sec-edgar","filing":"0001213900-22-065571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022065571/ownership.xml","form_type":"4"}},{"id":2223185,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":1800,"price":0.994,"value":1789.2,"ownership":{"direct":true},"balance_after":805000,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223184,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":100,"price":0.988,"value":98.8,"ownership":{"direct":true},"balance_after":803200,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223183,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":200,"price":0.982,"value":196.4,"ownership":{"direct":true},"balance_after":803100,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223182,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":2900,"price":0.993,"value":2879.7,"ownership":{"direct":true},"balance_after":802900,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2461340,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (to acquire Common Stock)","published_at":"2021-12-22T22:00:09.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted 200,000 stock options. The stock options have a ten-year term and vest over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter."}],"balance_after":200000,"derivative":{"exercise_price":1.44,"exercise_date":"2022-12-20","expiration_date":"2031-12-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-21-067062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390021067062/ownership.xml","form_type":"4"}},{"id":2461339,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T22:00:09.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person was granted Restricted Stock Units which shall vest into common stock of the Company over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001213900-21-067062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390021067062/ownership.xml","form_type":"4"}}]}